Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
44 results
D1.264 - Assessment by general practitioners of a therapeutic patient education guide for allergic patients
D1.262 - Clinical significance of a basophil activation test for Japanese beekeepers naturally sensitized to honey bee venom
D1.265 - Component-Resolved Diagnosis and Clinical Profiles of Anisakis Allergy in Japan
D1.266 - Investigation of anaphylaxis in mastocytosis mouse models
D1.267 - Recurrence of perioperative anaphylaxis: analysis of a multicenter cohort
D1.268 - The endothelial glycocalyx as a therapeutic target in anaphylaxis
D1.269 - Deciphering cardiovascular profiles in sera and extracellular vesicles from anaphylactic patients. Impact in endothelial cells
D1.270 - Anaphylaxis and Adrenaline: Knowledge gaps with critical consequences
D1.271 - Bovine gelatine-induced anaphylaxis brought on by eating beef, sweets containing gelatin, and medications
D1.272 - Efficacy and Safety of Omalizumab in Treating Severe Allergic Reactions with Urticaria as the Initial Symptom
D1.273 - Anaphylactic Reaction Following Sulphur Hexafluoride Administration
D2.167 - Effect of Metformin on allergen specific immunotherapy
D2.169 - Association of Antenatal Corticosteroid Treatment with Risk of Allergic Diseases in Children
D2.174 - Patient survey to determine the minimal clinically important difference for a combined symptom and medication score in grass AIT
D2.179 - Evaluation of Sublingual Immunotherapy for Cat Allergy: Results from a Non-Interventional Study
D2.168 - Systemic reactions to subcutaneous immunotherapy in children
D2.170 - The placebo effect leads to significantly lower values regarding allergic symptoms and medication use in birch-pollen allergic patients during the birch pollen season
D2.171 - The individual benefit of subcutaneous immunotherapy with mannan-conjugated birch pollen allergoids is already evident in the first season immediately after treatment
D2.172 - Subcutaneous immunotherapy with a depigmented cat allergoid in patients with cat allergy is safe and results primarily in delayed local reactions
D2.173 - Subcutaneous allergen-specific immunotherapies for inhalation allergens induce higher levels of therapy specific IgG4 antibodies than sublingual therapies: a retrospective data analysis
Pagination
Current page
1
Page
2
Page
3
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download